Obsidian Therapeutics, a biotechnology company, unveiled promising updates on its Phase 1 study of OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy, at the American Association for Cancer Research (AACR) Annual Meeting.

OBX-115 is being tested in patients with advanced melanoma who have not responded to immune checkpoint inhibitors (ICIs). Six patients received OBX-115 in the study, and the safety data collected over 25 weeks showed it was well-tolerated.

Crucially, OBX-115 demonstrated sustained and effective responses in reducing tumor growth. Rodabe N. Amaria, the study’s principal investigator, highlighted that OBX-115 is unique in not requiring interleukin 2 (IL2), a cytokine often used with TIL cell therapies but can cause severe side effects.

Parameswaran Hari, Obsidian’s Chief Development Officer, expressed optimism about OBX-115’s potential to expand the eligibility for TIL cell therapy and address the unmet need in ICI-resistant advanced melanoma. Obsidian is also conducting a multicenter Phase 1/2 study involving metastatic melanoma and non-small cell lung cancer patients.

Additionally, Obsidian presented three other posters at AACR 2024, detailing research on TILs engineered with membrane-bound IL15 and LIGHT (TNFSF14). These studies demonstrate Obsidian’s continued commitment to advancing engineered cell and gene therapies for treating cancer.

Source link: http://www.businesswire.com/news/home/20240409687216/en/Obsidian-Therapeutics-Presents-Positive-25-Week-Median-Study-Follow-Up-Safety-and-Efficacy-Data-from-First-in-Human-Study-of-OBX-115-in-Advanced-Melanoma-at-the-American-Association-for-Cancer-Research-Annual-Meeting

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.